

# Daniel Zips

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/373173/publications.pdf>

Version: 2024-02-01

134  
papers

4,784  
citations

101543

36  
h-index

114465

63  
g-index

138  
all docs

138  
docs citations

138  
times ranked

5787  
citing authors

#	ARTICLE	IF	CITATIONS
1	On the probability of lymph node negativity in pN0-staged prostate cancer—a theoretically derived rule of thumb for adjuvant needs. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 690-699.	2.0	1
2	Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 66-72.	2.0	0
3	Dynamics of HMBC1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 194-200.	2.0	7
4	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography—staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	5.4	26
5	Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 1-11.	2.0	9
6	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
7	The patients view on genetics and functional imaging for precision medicine: a willingness-to-pay analysis. <i>Personalized Medicine</i> , 2022, , .	1.5	1
8	Patient—individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis. <i>International Journal of Cancer</i> , 2022, 150, 1722-1733.	5.1	8
9	Clinical evaluation of autonomous, unsupervised planning integrated in MR-guided radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 229-233.	0.6	7
10	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC — Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.6	5
11	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. <i>Radiotherapy and Oncology</i> , 2022, 171, 30-36.	0.6	22
12	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
13	Simulation CT-based radiomics for prediction of response after neoadjuvant chemo-radiotherapy in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2022, 17, 84.	2.7	11
14	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	3.7	2
15	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	2.0	6
16	Quality of life and fatigue before and after radiotherapy in breast cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 281-287.	2.0	23
17	1.5T MR-linac planning study to compare two different strategies of rectal boost irradiation. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 86-91.	1.7	13
18	Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1606-1618.	0.8	52

#	ARTICLE	IF	CITATIONS
19	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.6	5
20	Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 567-580.	0.8	19
21	Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis). <i>Cancers</i> , 2021, 13, 1133.	3.7	6
22	Resistance of Hypoxic Cells to Ionizing Radiation Is Mediated in Part via Hypoxia-Induced Quiescence. <i>Cells</i> , 2021, 10, 610.	4.1	19
23	Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI. <i>Cancers</i> , 2021, 13, 1533.	3.7	14
24	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	2.0	11
25	Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1072-1087.	0.8	6
26	$\gamma$ H2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture. <i>Radiotherapy and Oncology</i> , 2021, 159, 119-125.	0.6	1
27	Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 155-160.	0.6	16
28	First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 159, 197-201.	0.6	23
29	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.6	37
30	Automatic 3D Monte-Carlo-based secondary dose calculation for online verification of 1.5T magnetic resonance imaging guided radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 6-12.	2.9	14
31	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
32	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
33	An Activity Tracker-Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). <i>JMIR Research Protocols</i> , 2021, 10, e28524.	1.0	1
34	A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling - Rationale and first in human. <i>Radiotherapy and Oncology</i> , 2021, 164, 37-42.	0.6	12
35	Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. <i>Biomolecules</i> , 2021, 11, 1561.	4.0	8
36	Automatic VMAT planning for post-operative prostate cancer cases using particle swarm optimization: A proof of concept study. <i>Physica Medica</i> , 2020, 69, 101-109.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Partial breast irradiation with the 1.5T MR-Linac: First patient treatment and analysis of electron return and stream effects. <i>Radiotherapy and Oncology</i> , 2020, 145, 30-35.	0.6	54
38	Depatux-M and temozolomide in advanced high-grade glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa063.	0.7	1
39	Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. <i>Cancers</i> , 2020, 12, 2795.	3.7	14
40	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	3.3	34
41	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 52-59.	2.9	2
42	Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 151, 182-189.	0.6	34
43	Quality assurance of IMRT treatment plans for a 1.5 T MR-linac using a 2D ionization chamber array and a static solid phantom. <i>Physics in Medicine and Biology</i> , 2020, 65, 16NT01.	3.0	20
44	A multi-institution study: comparison of the heating patterns of five different MR-guided deep hyperthermia systems using an anthropomorphic phantom. <i>International Journal of Hyperthermia</i> , 2020, 37, 1103-1115.	2.5	5
45	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	3.7	19
46	Image guidance in radiation therapy for better cure of cancer. <i>Molecular Oncology</i> , 2020, 14, 1470-1491.	4.6	63
47	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.6	41
48	Against Repurposing Methadone for Glioblastoma Therapy. <i>Biomolecules</i> , 2020, 10, 917.	4.0	8
49	PET/MRI and genetic inpatient heterogeneity in head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 542-551.	2.0	8
50	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
51	MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients. <i>Cancers</i> , 2020, 12, 959.	3.7	11
52	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 130, 10-17.	0.6	44
53	Quantitative, Multi-institutional Evaluation of MR Thermometry Accuracy for Deep-Pelvic MR-Hyperthermia Systems Operating in Multi-vendor MR-systems Using a New Anthropomorphic Phantom. <i>Cancers</i> , 2019, 11, 1709.	3.7	27
54	Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells. <i>Cancers</i> , 2019, 11, 110.	3.7	44

#	ARTICLE	IF	CITATIONS
55	Neutrophil-to-Lymphocyte Ratio in Rectal Cancerâ€”Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2448.	4.1	33
56	Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 771-779.	2.0	29
57	Organ Preservation in Rectal Cancer: The Patients' Perspective. <i>Frontiers in Oncology</i> , 2019, 9, 318.	2.8	44
58	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic <sup>18</sup> F-FMISO PET for Head and Neck Cancer Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1698-1704.	5.0	37
59	Intention-to-Treat Analysis of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1359-1365.	5.0	29
60	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.6	25
61	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 108-112.	1.7	9
62	Immunosuppressive Total Nodal Irradiationâ€”Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 137-143.	0.8	6
63	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2019, 110, 11-20.	2.8	44
64	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	7.0	67
65	Expressing cytotoxic compounds in <i>Escherichia coli</i> Nissle 1917 for tumor-targeting therapy. <i>Research in Microbiology</i> , 2019, 170, 74-79.	2.1	48
66	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.6	14
67	Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 93-100.	0.7	3
68	Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation. <i>JMIR MHealth and UHealth</i> , 2019, 7, e12345.	3.7	37
69	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 653-662.	4.2	11
70	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
71	Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 719-726.	2.0	9
72	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24

#	ARTICLE	IF	CITATIONS
73	Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas. <i>International Journal of Hyperthermia</i> , 2018, 34, 980-987.	2.5	11
74	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	5.1	50
75	Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2441.	4.1	22
76	Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 985-990.	2.0	5
77	Prospective data registration and clinical trials for particle therapy in Europe. <i>Radiotherapy and Oncology</i> , 2018, 128, 9-13.	0.6	20
78	Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients. <i>Radiotherapy and Oncology</i> , 2018, 128, 485-491.	0.6	32
79	Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 575-581.	0.6	16
80	Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 21-30.	1.5	29
81	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 437-444.	0.6	10
82	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. <i>Radiotherapy and Oncology</i> , 2017, 124, 526-532.	0.6	107
83	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncolmmunology</i> , 2017, 6, e1323161.	4.6	39
84	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. <i>Oncologist</i> , 2017, 22, 570-575.	3.7	23
85	Distortion correction of diffusion-weighted magnetic resonance imaging of the head and neck in radiotherapy position. <i>Acta Oncologica</i> , 2017, 56, 1659-1663.	1.8	12
86	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.6	123
87	Ex vivo $^3\text{H}2\text{AX}$ radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. <i>Radiotherapy and Oncology</i> , 2017, 124, 386-394.	0.6	18
88	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. <i>Acta Oncologica</i> , 2017, 56, 1571-1576.	1.8	23
89	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	1.7	16
90	Cell-line dependent effects of hypoxia prior to irradiation in squamous cell carcinoma lines. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 12-19.	1.7	14

#	ARTICLE	IF	CITATIONS
91	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 36-42.	1.7	9
92	TRPM8 is required for survival and radioresistance of glioblastoma cells. <i>Oncotarget</i> , 2017, 8, 95896-95913.	1.8	34
93	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1003-1013.	4.2	26
94	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.6	130
95	Clinical and Translational Radiation Oncology, a new player among the radiation oncology journals. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 1.	1.7	4
96	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.6	8
97	Conservative surgery with combined high dose rate brachytherapy for patients suffering from genitourinary and perianal rhabdomyosarcoma. <i>Radiotherapy and Oncology</i> , 2016, 121, 262-267.	0.6	32
98	Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 187-192.	2.5	22
99	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	7.0	127
100	Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 263-271.	0.8	6
101	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , 2016, 16, 234-249.	28.4	636
102	BK K+ channel blockade inhibits radiation-induced migration/brain infiltration of glioblastoma cells. <i>Oncotarget</i> , 2016, 7, 14259-14278.	1.8	54
103	Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. <i>Radiation Oncology</i> , 2015, 10, 138.	2.7	8
104	Ca <sup>2+</sup> -Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells. <i>Molecular Cancer Research</i> , 2015, 13, 1283-1295.	3.4	42
105	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1165-1174.	0.8	89
106	Chronic graft-versus-host-disease in CD34+ humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. <i>Journal of Autoimmunity</i> , 2015, 62, 55-66.	6.5	38
107	<sup>3</sup> H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , 2015, 116, 473-479.	0.6	38
108	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. <i>Acta Oncologica</i> , 2015, 54, 1355-1363.	1.8	57



#	ARTICLE	IF	CITATIONS
109	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. <i>Acta Oncologica</i> , 2015, 54, 1364-1369.	1.8	22
110	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. <i>Acta Oncologica</i> , 2015, 54, 1658-1664.	1.8	36
111	Residual $\gamma$ H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , 2015, 116, 480-485.	0.6	37
112	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. <i>Radiotherapy and Oncology</i> , 2014, 113, 303-309.	0.6	79
113	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.6	141
114	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. <i>Radiation Oncology</i> , 2014, 9, 261.	2.7	9
115	Effect of $^{18}\text{F}$ FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. <i>Radiotherapy and Oncology</i> , 2014, 111, 81-87.	0.6	34
116	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. <i>Radiotherapy and Oncology</i> , 2014, 110, 362-369.	0.6	49
117	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 159-166.	0.8	29
118	Place of Proton Radiotherapy in Future Radiotherapy Practice. <i>Seminars in Radiation Oncology</i> , 2013, 23, 149-153.	2.2	11
119	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. <i>Radiotherapy and Oncology</i> , 2012, 102, 444-449.	0.6	26
120	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. <i>Radiotherapy and Oncology</i> , 2012, 105, 21-28.	0.6	262
121	Exploratory Study of the Prognostic Value of Microenvironmental Parameters During Fractionated Irradiation in Human Squamous Cell Carcinoma Xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1205-1213.	0.8	61
122	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1019-1028.	2.4	26
123	Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2010, 96, 116-122.	0.6	80
124	Cancer stem cells and radiotherapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 391-402.	1.8	75
125	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , 2009, 92, 405-410.	0.6	22
126	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2007, 83, 304-310.	0.6	144



#	ARTICLE	IF	CITATIONS
127	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 256-264.	2.0	64
128	Experimental Evaluation of Functional Imaging for Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 41-42.	2.0	6
129	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 80, 112-122.	0.6	78
130	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. <i>Radiotherapy and Oncology</i> , 2006, 81, 122-129.	0.6	102
131	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. <i>Radiotherapy and Oncology</i> , 2005, 74, 331-336.	0.6	20
132	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <i>Radiotherapy and Oncology</i> , 2005, 76, 151-156.	0.6	27
133	Selection of Genetically Distinct, Rapidly Proliferating Clones does not Contribute to Repopulation during Fractionated Irradiation in FaDu Squamous Cell Carcinoma. <i>Radiation Research</i> , 2003, 160, 257-262.	1.5	1
134	Splicing Mutations in TP53 in Human Squamous Cell Carcinoma Lines Influence Immunohistochemical Detection. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 197-204.	2.5	64